Related Experiment Video

Updated: Apr 20, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.5K

Association of early caffeine administration and neonatal outcomes in very preterm neonates

Abhay Lodha1, Mary Seshia2, Douglas D McMillan3

  • 1Department of Pediatrics and Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

JAMA Pediatrics
|November 18, 2014
PubMed

Insights

Early caffeine therapy for very preterm infants reduced the risk of death or bronchopulmonary dysplasia and patent ductus arteriosus. This prophylactic approach showed no adverse effects on other neonatal outcomes.

Area of Science:

  • Neonatalogy
  • Pharmacology
  • Critical Care Medicine

Background:

  • Caffeine is recognized for its benefits in managing apnea of prematurity.
  • Clinicians increasingly use caffeine prophylactically in preterm infants, even before apnea onset.

Purpose of the Study:

  • To investigate the impact of early caffeine therapy initiation on neonatal outcomes.
  • To assess the effects in very preterm infants born in Canada.

Main Methods:

  • Retrospective cohort study of preterm neonates (<31 weeks' gestation) across 29 Canadian NICUs (2010-2012).
  • Caffeine therapy initiation was categorized as early (within 2 days) or late (on/after day 3).
  • Primary composite outcome: death or bronchopulmonary dysplasia.

Main Results:

  • Over 5000 infants received caffeine; 74.6% started early.
  • Early caffeine initiation was linked to reduced odds of death or bronchopulmonary dysplasia (aOR, 0.81) and patent ductus arteriosus (aOR, 0.74).
  • No significant differences observed in mortality, necrotizing enterocolitis, severe neurological injury, or severe retinopathy of prematurity.

Conclusions:

  • Early prophylactic caffeine administration in very preterm neonates is associated with improved outcomes.
  • Reduced rates of death or bronchopulmonary dysplasia and patent ductus arteriosus were observed.
  • The study found no adverse effects on other critical neonatal health indicators.
Abstract

More Related Videos

Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates05:58

Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates

Published on: September 6, 2017

41.3K
Preterm EEG: A Multimodal Neurophysiological Protocol19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

29.2K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
944
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
895
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
373
Experimental Designs01:16

Experimental Designs

An experimental design is a systematic process that allows researchers to evaluate the relationship between dependent and independent variables. There are three widely used types of experimental design - pre-experimental design, true experimental design, and quasi-experimental design. In pre-experimental design, the researcher compares the data before and after some interventions or treatments. The true-experimental design has more than one purposefully created group, a commonly measured...
18.7K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.3K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
518